From: Mesenchymal stem cells-derived exosomes for drug delivery
RNA | Exosomes origin | Loading methods | Administration route | Model | Aim | References |
---|---|---|---|---|---|---|
miR-122 | AMSC | Transfection | Intra-tumor injection | Mice | Enhance HCC chemosensitivity | [34] |
miRNA-181-5p | AMSC | Transfection | Intrasplenic injection | Mice | Prevent liver fibrosis | [67] |
microRNA-584 | BMSCs | Transfection | Local injection | Mice | Reduce glioma activity | [62] |
miR-132 | BMSCs | Electroporation | Local injection | Mice | Promote angiogenesis | [107] |
LNA-anti-miR-142-3p | BMSCs | Electroporation | Intravenous injection | Mice | Reduce tumorigenicity of breast cancer | [88] |
miR-379 | BMSCs | Transfection | Intravenous injection | Mice | Reduce breast cancer activity | [72] |
miR-124 | WJMSCs | Transfection | In vitro experiment | GBM cancer cells | Reduce glioblastoma multiform cells activity | [73] |
miR-133b | BMSCs | Transfection | Intravenous injection | Mice | Neuroprotective role | [64] |
miR-145-5p | HucMSCs | Transfection | Intra-tumor injection | Mice | Inhibit pancreatic ductal adenocarcinoma | [91] |
miR-675 | HucMSCs | Transfection | Local injection | Mice | Treat aging-induced vascular dysfunction | [110] |
miR-126 | BMSCs | Transfection | In vitro cell experiment | N/A | Ameliorate hypoxia/reoxygenation-injured ECs | [108] |
miR-644-5p | BMSCs | Transfection | Intravenous injection | Cisplatin-induced POF mouse mode | Inhibit ovarian granulosa cell apoptosis | [74] |
miR-34a | BMSC | Transfection | Intravenous injection | Mice | Reduce GBM activity | [93] |
miR-29b | BMSC | Transfection | Intravenous injection | Mice | Repair spinal cord injury in rats | [63] |
tsRNA-10277 | BMSC | Transfection | In vitro cell experiment | N/A | Enhance osteogenic differentiation ability of dexamethasone-induced BMSCs | [75] |
miR-126 | BMSC | Transfection | Intravenous injection | Rats | Promote repair after spinal cord injury | [68] |
MiR-29 | BMSC | Transfection | Local injection | Rats | Potential treatments for AD | [96] |
miR-499 | BMSC | Electroporation | Intratumorally injected | Mice | Inhibit endometrial cancer growth and metastasis | [76] |
miR-544 | BMSCs | Transfection (incubate together) | Intravenous injection | Rats | Promote repair after spinal cord injury | [97] |
miR-199a | AMSCs | Transfection | Intravenous injection | Mice | Improve HCC chemosensitivity | [66] |
miR-29a | BMSCs | Transfection | Intravenous injection | Mice | Promote angiogenesis and osteogenesis | [112] |
LNA-antimiR-142-3p | BMSCs | Electroporation | In vitro cell experiment | Mice | Reduce the tumorigenicity of breast cancer stem cells in vivo | [89] |
miRNA-126-3p | HucMSCs | Transfection | In vitro cell experiment and intravenous injection | Mice | Enhance endothelial function and attenuate vein graft neointimal formation | [77] |
miR-326 | HucMSC | Transfection | Intravenous injection | Mice | Relieve DSS-induced IBD | [78] |
miR-19a/19b | BMSCs | Transfection | Intravenous injection | Mice | Mitigate the damage of myocardial infarction | [70] |
MiR-17–92 | BMSCs | Transfection | Intravenous injection | Mice | Enhance axon-myelin remodeling and motor electrophysiological recovery after stroke | [65] |
miR-124 | BMSCs | Transfection | Subcutaneous injection | Mice | Treatment of pancreatic tumors | [71] |
miR-124 | HADMSCs | Transfection | In vitro cell experiment | M17 human NB cell line | Therapy for NB cancer | [79] |
miR-214 | BMSCs | Transfection | Intracerebroventricular injection | Rats | Neuroprotection against cerebral | [80] |
miR-381 | ADMSC | Electroporation | In vitro cell experiment | MDA-MB-231 cells | Inhibit triple-negative breast cancer aggressiveness | [81] |
aiR-34a | Dental pulp MSCs (DPSCs) | Transfection (Lentiviral miR-34a transduction) | In vitro cell experiment | MDA-MB-231 cells | Repress proliferation of breast carcinoma cells | [82] |
miR-135B | BMSCs | Transfection | Articular cavity injection | OA rat model | Attenuate the damage of cartilage tissues | [83] |
miR-155-5P | Synovial MSCs (SMSCs) | Transfection | Articular cavity injection | OA rat model | OA therapy | [84] |
miR-126 | BMSCs | Transfection | In vitro cell experiment | Human umbilical vein endothelial cells | Pro-angiogenic potential | [85] |
MicroRNA-let7c | BMSCs | Lentiviral transduction | Administered intravenously | Rats | Attenuate renal fibrosis | [86] |
PTEN-siRNA | BMSCs | Incubated | Intranasal injection | Rats | Promote recovery for SCI | [98] |
miR-21 | HucMSC | Transfection | In vitro cell experiment | β-cells | Treatment of diabetes | [100] |
miR-375 | BMSCs | Transfection | In vitro cell experiment | β-cells | Treatment of diabetes | [101] |
miR-125a | ADMSC | Transfection | Intravenous injection | Rats | Diabetic nephropathy | [104] |
miR-126 | HucMSC | Transfection | Local injection | Rats | Diabetic eye diseases | [105] |
lncRNA H19 | BMSCs | Transfection | Local injection | Rats | Diabetic foot ulcer | [106] |